Logo image of MOR

MorphoSys AG (MOR) Stock Price, Quote, News and Overview

NASDAQ:MOR - Nasdaq - US6177602025 - ADR - Currency: USD

18.96  +0.45 (+2.43%)

After market: 18.96 0 (0%)

MOR Quote, Performance and Key Statistics

MorphoSys AG

NASDAQ:MOR (8/2/2024, 8:20:34 PM)

After market: 18.96 0 (0%)

18.96

+0.45 (+2.43%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High19.5
52 Week Low4.18
Market Cap2.86B
Shares150.65M
Float18.44M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-29 2024-08-29/amc
IPO03-09 1999-03-09


MOR short term performance overview.The bars show the price performance of MOR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

MOR long term performance overview.The bars show the price performance of MOR in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of MOR is 18.96 USD. In the past month the price increased by 1.94%. In the past year, price increased by 144.65%.

MorphoSys AG / MOR Daily stock chart

MOR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About MOR

Company Profile

MOR logo image MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Company Info

MorphoSys AG

Semmelweisstr. 7

Planegg BAYERN 82152 DE

CEO: Jean-Paul Kress

Employees: 464

Company Website: https://www.morphosys.com

Phone: 4989899270

MorphoSys AG / MOR FAQ

What is the stock price of MorphoSys AG today?

The current stock price of MOR is 18.96 USD. The price increased by 2.43% in the last trading session.


What is the ticker symbol for MorphoSys AG stock?

The exchange symbol of MorphoSys AG is MOR and it is listed on the Nasdaq exchange.


On which exchange is MOR stock listed?

MOR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MorphoSys AG stock?

12 analysts have analysed MOR and the average price target is 5.06 USD. This implies a price decrease of -73.33% is expected in the next year compared to the current price of 18.96. Check the MorphoSys AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MorphoSys AG worth?

MorphoSys AG (MOR) has a market capitalization of 2.86B USD. This makes MOR a Mid Cap stock.


How many employees does MorphoSys AG have?

MorphoSys AG (MOR) currently has 464 employees.


What are the support and resistance levels for MorphoSys AG (MOR) stock?

MorphoSys AG (MOR) has a support level at 18.58 and a resistance level at 19. Check the full technical report for a detailed analysis of MOR support and resistance levels.


Is MorphoSys AG (MOR) expected to grow?

The Revenue of MorphoSys AG (MOR) is expected to decline by -3.33% in the next year. Check the estimates tab for more information on the MOR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MorphoSys AG (MOR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MorphoSys AG (MOR) stock pay dividends?

MOR does not pay a dividend.


When does MorphoSys AG (MOR) report earnings?

MorphoSys AG (MOR) will report earnings on 2024-08-29, after the market close.


What is the Price/Earnings (PE) ratio of MorphoSys AG (MOR)?

MorphoSys AG (MOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.38).


MOR Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to MOR. When comparing the yearly performance of all stocks, MOR is one of the better performing stocks in the market, outperforming 98.16% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MOR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MOR. MOR has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MOR Financial Highlights

Over the last trailing twelve months MOR reported a non-GAAP Earnings per Share(EPS) of -3.38. The EPS decreased by -160.42% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -25.13%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-518.18%
Sales Q2Q%-55.81%
EPS 1Y (TTM)-160.42%
Revenue 1Y (TTM)-31.97%

MOR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 70% to MOR. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 20.86% and a revenue growth -3.33% for MOR


Ownership
Inst Owners1.03%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts70
Price Target5.06 (-73.31%)
EPS Next Y20.86%
Revenue Next Year-3.33%